Market Size in 2022 | Market Forecast in 2030 | CAGR (in %) | Base Year |
---|---|---|---|
USD 15.37 Billion | USD 23.14 Billion | 5.19% | 2022 |
The global neutropenia treatment market size was worth around USD 15.37 Billion in 2022 and is predicted to grow to around USD 23.14 Billion by 2030 with a compound annual growth rate (CAGR) of roughly 5.19% between 2023 and 2030. The report analyzes the global neutropenia treatment market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the neutropenia treatment industry.
Global Neutropenia Treatment Market: Overview
In Global Neutropenia Treatment Market Report, Neutropenia is a blood condition that is characterized by low levels of neutrophils that help to protect the body from infection. Neutropenia can be due to infection or as a result of cancer treatment. Depending on the number of neutrophils in the sample of the blood, neutropenia is categorized as severe, moderate, or mild. Some types of neutropenia may not require treatment but in the case of febrile neutropenia, treatment is essential as it may also lead to death.
Major factors that are driving the growth of the global market are the rise in prevalence of chemotherapy-induced neutropenia, the growing need for efficient & effective treatment, and the easy availability of the drugs through online pharmacies. As per the data published by CDC, in the United States, every year nearly 650,000 cancer patients undergo chemotherapy in an outpatient oncology clinic. These patients are at a high risk of developing neutropenia which is recognized as the most serious hematologic toxicity as a result of cancer treatment with chemotherapy. This leads to disruptions in chemotherapy schedules, hospitalization, and in some cases death.
All such factors coupled with the growing prevalence of infections such as sepsis, tuberculosis & hepatitis, and autoimmune diseases including rheumatoid arthritis, lupus, and Crohn’s disease are fostering the growth of the global neutropenia treatment market. In addition to this, a rise in the number of clinical trials for neutropenia treatment and an increase in mergers & acquisitions by the pharmaceuticals to expand the business & pipeline drugs are also some of the major factors that are contributing to the growth of the global market.
Moreover, factors such as heavy investments in R&D activities and the rise in outsourcing of drug discovery & development projects are also contributing to the growth of the global market. Furthermore, technological advancements for the development of innovative products for effective treatment can provide several opportunities for the growth of the global neutropenia treatment market over the forecast period. However, strict regulations imposed by the regulatory bodies for the approval may limit the growth of the global neutropenia treatment market.
The global neutropenia treatment market is moderately affected by the outbreak of the Covid-19 pandemic. The shutdown of the manufacturing units, temporary halt on clinical trials, and postponement of non-emergency cases due to the strict lockdown and restriction on movement in the first half of the year 2020 have affected the manufacture of drugs & biologics necessary for the neutropenia treatment. On the other hand, the online sales of drugs and drop in the platelet count in some Covid-19 positive patients are witnessed to support the growth of the global market during the pandemic.
The global neutropenia treatment market is divided based on treatment, distribution channel, and region.
Based on treatment, the global neutropenia treatment market is split into antivirals, anti-fungals, antibiotics, and colony-stimulating factors. Among these, the colony-stimulating factor segment is anticipated to lead the global market due to the rise in focus of manufacturers on colony-stimulating factor-based drugs.
The distribution channel is bifurcated into online pharmacies, retail pharmacies, and hospital pharmacies. Among these, the hospital pharmacies segment is expected to hold the largest share in the market.
Report Attributes | Report Details |
---|---|
Report Name | Neutropenia Treatment Market Research Report |
Market Size in 2022 | USD 15.37 Billion |
Market Forecast in 2030 | USD 23.14 Billion |
Growth Rate | CAGR of 5.19% |
Number of Pages | 214 |
Key Companies Covered | Amgen, Teva Pharmaceutical Industries Ltd., Spectrum Pharmaceuticals, Pfizer, Partner Therapeutics, Novartis AG, Mylan N.V., Cellerant Therapeutics, Kyowa Kirin, and BeyondSpring. |
Segments Covered | By Treatment, By Distribution Channel, And By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2022 |
Historical Year | 2017 to 2021 |
Forecast Year | 2023 - 2030 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America is anticipated to dominate the global neutropenia treatment market during the forecast period. The rise in prevalence of chemotherapy-induced neutropenia especially in the US is the chief factor that is spurring the growth of the market in this region. In addition to this, the presence of advanced technology, huge investment in research & development, and favorable reimbursement policies are also some of the factors that are fueling the growth of the market in North America. Asia Pacific is estimated to be the fastest-growing region in the market. This is attributing to the rise in expenditure on healthcare, growing cases of cancer, and growing prevalence of infections in under-developed countries.
By Treatment
By Distribution Channel
By Region
FrequentlyAsked Questions
Neutropenia is a blood condition that is characterized by low levels of neutrophils that help to protect the body from infection. Neutropenia can be due to infection or as a result of cancer treatment. Depending on the number of neutrophils in the sample of the blood, neutropenia is categorized as severe, moderate, or mild.
The global neutropenia treatment market size was worth around USD 15.37 Billion in 2022 and is predicted to grow to around USD 23.14 Billion by 2030.
The CAGR value of the neutropenia treatment market is expected to be around 5.19% during 2023-2030.
North America is anticipated to dominate the global neutropenia treatment market during the forecast period. The rise in prevalence of chemotherapy-induced neutropenia especially in the US is the chief factor that is spurring the growth of the market in this region.
Some of the key players operating in the global neutropenia treatment market include Amgen, Teva Pharmaceutical Industries Ltd., Spectrum Pharmaceuticals, Pfizer, Partner Therapeutics, Novartis AG, Mylan N.V., Cellerant Therapeutics, Kyowa Kirin, and BeyondSpring.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed